

ASX Announcement
11 November 2019

RESULTS OF ANNUAL GENERAL MEETING

Notice is hereby given, in accordance with Listing Rule 3.13.2 and Corporations Law Section 251AA(2) that at the Annual General Meeting (**AGM**) of Anteo Diagnostics Ltd (the **Company**) held today that the resolutions as set out below were passed by a show of hands without amendment.

Resolution 1 – Advisory Resolution

“To adopt the Directors’ Remuneration Report for the year ended 30 June 2019.”

Resolution 2 – Ordinary Resolution

“That Geoffrey Cumming, who retires in accordance with the Company’s Constitution and, being eligible, offers himself for re-election, is hereby re-elected a director of the Company”.

Resolution 3 – Ordinary Resolution

“That Christopher Parker, who retires in accordance with the Company’s Constitution and, being eligible, offers himself for re-election, is hereby re-elected a director of the Company”.

Resolution 4 – Ordinary Resolution

“That, for the purposes of ASX Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue of 99,999,508 Placement Shares on the terms and conditions set out in the Explanatory Statement.”

Resolution 5 – Ordinary Resolution

“That, for the purposes of ASX Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue of 49,999,724 Placement Options on the terms and conditions set out in the Explanatory Statement.”

Resolution 6 – Ordinary Resolution

“That, for the purposes of ASX Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue of 29,211,716 Fee Options on the terms and conditions set out in the Explanatory Statement.”

Resolution 7 – Special Resolution

“That, in accordance with Section 157 of the Corporations Act 2001 (Cth), the Company adopts the new name AnteoTech Limited and Shareholders approve the Company changing its name to AnteoTech Limited with the effect from the day on which the Australian Securities and Investments Commission alters the details of the Company’s registration.”

Resolution 8 – Special Resolution

“That, pursuant to and in accordance with Listing Rule 7.1A and for all other purposes, shareholders approve the issue of equity securities up to 10% of the issued capital of the Company calculated in accordance with the formula prescribed in Listing Rule 7.1A.2 and on the terms and conditions in the Explanatory Memorandum.”

For personal use only

Resolution 9 – Ordinary Resolution
RESOLUTION WITHDRAWN

In respect of the resolutions, the total number of proxy votes exercisable by all proxies validly appointed and the total number of proxy votes in respect of which the appointments specified that:

- I. The proxy was to vote for the resolution; and
- II. The proxy was to vote against the resolution; and
- III. The proxy was able to vote at the proxy's discretion; and
- IV. The proxy abstained from voting

are set out below:

Resolution	For	Against	Discretion	Abstain	Total
1	394,831,302	10,306,997	59,055,484	48,974,537	513,168,320
2	426,069,839	26,269,839	59,490,984	1,337,658	513,168,320
3	441,294,839	11,044,839	59,490,984	1,337,658	513,168,320
4	442,044,554	7,838,114	59,897,555	3,388,097	513,168,320
5	442,006,725	7,875,943	59,897,555	3,388,097	513,168,320
6	443,100,769	7,236,443	59,897,555	2,933,553	513,168,320
7	445,270,808	8,002,482	59,502,201	392,829	513,168,320
8	330,972,227	121,158,956	59,897,555	1,139,582	513,168,320
9	-	-	-	-	-

On behalf of the Board
 DP Cornish
 Company Secretary

ABOUT ANTEO GROUP – Anteo Diagnostics Limited (ADO:ASX)

Anteo Group is a surface chemistry company with intellectual property in its core technology product groups AnteoCoat™, AnteoBind™ and AnteoRelease™. The Company's purpose is to create shareholder value by identifying and solving important global industry problems by providing unique value-added solutions for its customers. Anteo's customers operate in the life sciences, diagnostics, energy and medical devices markets.

For more information, please contact:

Jack Hamilton, Chairman, Anteo Diagnostics Limited: +61 7 3219 0085
 Ben Jarvis, Six Degrees Investor Relations: +61 (0) 413 150 448



Follow Anteo Diagnostics on Twitter:

<https://twitter.com/AnteoDX> or visit www.anteotech.com

For personal use only